TY - JOUR
T1 - Use and effectiveness of dapagliflozin in routine clinical practice. An Italian multicenter retrospective study
AU - Giaccari, Andrea
AU - Fadini, Gian Paolo
AU - Zatti, Giancarlo
AU - Baldi, Ileana
AU - Bottigliengo, Daniele
AU - Consoli, Agostino
AU - Sesti, Giorgio
AU - Avogaro, Angelo
PY - 2018
Y1 - 2018
N2 - In randomized controlled trials (RCTs), SGLT-2 inhibitors (SGLT2i) showed glycaemic and extra-glycaemic benefits. The DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) was a multicenter retrospective study designed to evaluate baseline characteristics of patients receiving dapagliflozin versus selected comparators (DPP-4 inhibitors, gliclazide, or GLP-1 receptor agonists), and drug effectiveness in routine clinical practice. From a population of 281,217 patients, the analysis included 17,285 initiating dapagliflozin or comparator glucose lowering medications (GLM), 6751 of whom had a follow-up examination. At baseline, patients starting dapagliflozin were younger, had a longer disease duration, higher HbA1c, and a more complex history of previous GLM use, but the clinical profile of patients receiving dapagliflozin was changing during the study period. Dapagliflozin reduced HbA1c by 0.7%, body weight by 2.7 kg, and systolic blood pressure by 3.0 mm Hg. Effects of comparator GLM were also within the expected range based on RCTs. This real-world study demonstrates an initial channelling of dapagliflozin to difficult-to-treat patients. Nonetheless, dapagliflozin provided significant benefits on glucose control, body weight, and blood pressure that were in line with findings from RCTs.
AB - In randomized controlled trials (RCTs), SGLT-2 inhibitors (SGLT2i) showed glycaemic and extra-glycaemic benefits. The DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) was a multicenter retrospective study designed to evaluate baseline characteristics of patients receiving dapagliflozin versus selected comparators (DPP-4 inhibitors, gliclazide, or GLP-1 receptor agonists), and drug effectiveness in routine clinical practice. From a population of 281,217 patients, the analysis included 17,285 initiating dapagliflozin or comparator glucose lowering medications (GLM), 6751 of whom had a follow-up examination. At baseline, patients starting dapagliflozin were younger, had a longer disease duration, higher HbA1c, and a more complex history of previous GLM use, but the clinical profile of patients receiving dapagliflozin was changing during the study period. Dapagliflozin reduced HbA1c by 0.7%, body weight by 2.7 kg, and systolic blood pressure by 3.0 mm Hg. Effects of comparator GLM were also within the expected range based on RCTs. This real-world study demonstrates an initial channelling of dapagliflozin to difficult-to-treat patients. Nonetheless, dapagliflozin provided significant benefits on glucose control, body weight, and blood pressure that were in line with findings from RCTs.
KW - 3003
KW - Antidiabetic drugs
KW - Drug Discovery3003 Pharmaceutical Science
KW - Glycemic control
KW - Glycosylated hemoglobin
KW - Pharmacology
KW - Precision medicine
KW - Sodium-glucose cotransporter 2 inhibitors
KW - Type 1 diabetes mellitus
KW - Type 2 diabetes melÂlitus
KW - Weight reduction
KW - 3003
KW - Antidiabetic drugs
KW - Drug Discovery3003 Pharmaceutical Science
KW - Glycemic control
KW - Glycosylated hemoglobin
KW - Pharmacology
KW - Precision medicine
KW - Sodium-glucose cotransporter 2 inhibitors
KW - Type 1 diabetes mellitus
KW - Type 2 diabetes melÂlitus
KW - Weight reduction
UR - http://hdl.handle.net/10807/116501
U2 - 10.1111/dom.13280
DO - 10.1111/dom.13280
M3 - Article
SP - N/A-N/A
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
ER -